LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

Home・Aandelen Lijst・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Gesloten

SectorGezondheidszorg

68.94 -1.49

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

68.43

Max

70.23

Belangrijke statistieken
By Trading Economics
Inkomsten	292M 150M
Verkoop	-75M 377M
K/W Sectorgemiddelde	25.941 51.415
Winstmarge	39.832
Werknemers	423
EBITDA	-97M 185M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+20.63% upside

Dividenden
By Dow Jones
Volgende Winsten	4 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	218M 7.9B
Vorige openingsprijs	70.43
Vorige sluitingsprijs	68.94

Nieuwssentiment

By Acuity

14%

86%

22 / 346 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

60.49 / 70.14 Steun & Weerstand

Halozyme Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 mei 2026, 22:44 UTC

Acquisities, Fusies, Overnames

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14 mei 2026, 22:27 UTC

Acquisities, Fusies, Overnames

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14 mei 2026, 22:12 UTC

Winsten

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14 mei 2026, 21:52 UTC

Acquisities, Fusies, Overnames

LVMH to Sell Marc Jacobs

15 mei 2026, 00:00 UTC

Winsten

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14 mei 2026, 23:57 UTC

Acquisities, Fusies, Overnames

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14 mei 2026, 23:56 UTC

Acquisities, Fusies, Overnames

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14 mei 2026, 23:56 UTC

Acquisities, Fusies, Overnames

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14 mei 2026, 23:56 UTC

Marktinformatie

Gold Prices Rise on Strong Demand -- Market Talk

14 mei 2026, 23:56 UTC

Acquisities, Fusies, Overnames

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14 mei 2026, 23:50 UTC

Marktinformatie

Global Equities Roundup: Market Talk

14 mei 2026, 23:50 UTC

Marktinformatie

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14 mei 2026, 23:47 UTC

Winsten

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14 mei 2026, 23:47 UTC

Winsten

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14 mei 2026, 23:46 UTC

Winsten

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14 mei 2026, 23:46 UTC

Winsten

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14 mei 2026, 23:28 UTC

Marktinformatie

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14 mei 2026, 23:00 UTC

Marktinformatie

Australia's One Nation Party Leads In The Polls -- Market Talk

14 mei 2026, 22:46 UTC

Marktinformatie

Global Equities Roundup: Market Talk

14 mei 2026, 22:46 UTC

Marktinformatie

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14 mei 2026, 22:46 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

14 mei 2026, 22:35 UTC

Marktinformatie

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14 mei 2026, 22:11 UTC

Acquisities, Fusies, Overnames

LVMH Agrees to Sell Marc Jacobs -- WSJ

14 mei 2026, 22:06 UTC

Marktinformatie

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14 mei 2026, 22:04 UTC

Winsten

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14 mei 2026, 22:04 UTC

Winsten

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14 mei 2026, 22:04 UTC

Winsten

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14 mei 2026, 22:00 UTC

Winsten

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14 mei 2026, 21:55 UTC

Winsten

Nu Holdings 1Q EPS 18c >NU

14 mei 2026, 21:55 UTC

Winsten

Nu Holdings 1Q Rev $4.97B >NU

Peer Vergelijking

Prijswijziging

Halozyme Therapeutics Inc Prognose

Koersdoel

By TipRanks

20.63% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 84.48 USD 20.63%

Hoogste 96 USD

Laagste 66.41 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Halozyme Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Halozyme Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

60.49 / 70.14Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

22 / 346 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.